Lipitor, a widely used cholesterol-lowering medication, belongs to the statin class of drugs. Statins inhibit the enzyme HMG-CoA reductase, which plays a central role in cholesterol production within the liver. A study on statin-induced changes in the liver identified that Lipitor alters the expression of several protein synthesis enzymes (1).

Researchers found that Lipitor treatment reduces the levels of eIF4A, a translation initiation factor that facilitates mRNA translation and protein synthesis (2). This decrease in eIF4A levels may contribute to the reduction in protein synthesis observed in response to Lipitor treatment.

Furthermore, another study discovered that Lipitor decreases the expression of ribosomal protein L37 (RPL37), a crucial component of the large ribosomal subunit necessary for protein synthesis (3).

Additionally, a research review indicates that statins may also affect the expression of other translation regulators, such as 4EBP1, which interacts with eIF4E to regulate protein synthesis (4).

While the specific mechanisms by which Lipitor and other statins alter protein synthesis enzymes are complex and multifaceted, research has shown that these drugs can impact the translation machinery in various ways to ultimately reduce cholesterol production in the liver.

Sources:
1. https://www.dugpatentwatch.com
2. [2]
https://pubmed.ncbi.nlm.nih.gov/12441349/
3. [3]
https://www.ncbi.nlm.nih.gov/gene/6047/
4. [4]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441946/